Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scholar Rock HoldingFRA:2QK -4.72%30 3-Year RORE % is 15.66 as of Mar. 2026. GuruFocus rates FRA:2QK with a GF Score™ of 30/100. The stock has 5 warning signs investors should review. Among 1,292 Biotechnology companies, Scholar Rock Holding ranks better than 79.57% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Scholar Rock Holding's 3-Year RORE % for the quarter that ended in Mar. 2026 was 15.66%.
The industry rank for Scholar Rock Holding's 3-Year RORE % or its related term are showing as below:
FRA:2QK's 3-Year RORE % is ranked better than 79.57% of 1292
companies
in the Biotechnology industry
Industry Median: -11.39
vs FRA:2QK: 15.66
Scholar Rock Holding (FRA:2QK) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Scholar Rock Holding 3-Year RORE % Related Terms
Scholar Rock Holding 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Scholar Rock Holding's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2QK vs COGT, CGON, PTCT: 3-Year RORE % Comparison
For the Biotechnology subindustry, Scholar Rock Holding's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Scholar Rock Holding (FRA:2QK) has a 3-Year RORE % of 15.66 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Scholar Rock Holding and its competitors. According to the industry distribution chart, Scholar Rock Holding ranks #264 out of 1292 companies in the Biotechnology industry, placing it in the top 20.4%.
Is Scholar Rock Holding's 3-Year RORE % too high?
Scholar Rock Holding's current 3-Year RORE % is 15.66. Based on the distribution chart, Scholar Rock Holding ranks #264 out of 1292 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Scholar Rock Holding has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's 3-Year RORE % compare to COGT and CGON?
According to the Biotechnology industry distribution chart, Scholar Rock Holding ranks #264 out of 1292 companies for 3-Year RORE %. This places Scholar Rock Holding in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Scholar Rock Holding and its competitors. Scholar Rock Holding's current 3-Year RORE % is 15.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Scholar Rock Holding (FRA:2QK) has a current 3-Year RORE % of 15.66. The current 3-Year RORE % is 15.66. Scholar Rock Holding's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current 3-Year RORE % is 15.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
30GF Score
Get the complete analysis for FRA:2QK
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QK has been successfully added to your 
